Lowest Price Guaranteed From USD 4,799
Companies Covered
95
Pages
290
View Count
9865
The Fc region and glycoengineered antibodies market is estimated to be worth $21.6 billion in 2021 and is expected to grow at CAGR of 5% during the forecast period. With close to 100 approved monoclonal fc antibodies, and over 550 molecules in the clinical pipeline, antibody based pharmacological interventions have become one of the fast growing segment of the biopharmaceutical industry. In fact, these interventions are anticipated to generate a cumulative sales of USD 300 billion by 2025. Further, within the antibody therapeutics industry, engineered antibodies, developed by modifying the fragment crystallizable (Fc) region, have garnered significant interest over the past few years. The modifications (such as glycoengineering, protein engineering or isotype chimerism) in the Fc region of an antibody have shown to augment the various effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP) activity and / or the half-life of the molecule. Moreover, several Fc engineering technologies enable the suppression of the effector functions in certain pathways, and are being actively exploited for development of anti-cancer antibodies.
Over time, a substantial body of evidence has validated the therapeutic applications of Fc engineering platforms, which, in turn, has led to the establishment of numerous strategic partnerships (focused on therapy development and clinical research) and significant investment into the innovator companies. The consistent research efforts in this domain have translated into the emergence of two blockbuster drugs, namely Gazyva® (for Chronic Lymphocytic Leukemia) and POTELEGIO® (for Sézary syndrome) and several other Fc engineered antibody products, including Margenza™, MONJUVI® and SKYRIZI™ that received approval in the past few years. More recently, in 2021, two Fc engineered antibodies, namely Sotrovimab and Etesevimab, got approved for the treatment of COVID-19. Further, there are several drugs in the development pipeline, which are being investigated by various small and established pharmaceutical companies. The promising clinical results, and ongoing technical developments, coupled to the growing interest of biopharmaceutical developers, are anticipated to give the required impetus to the push pipeline products to higher stages of development, and commercialization. We believe that the market is likely to witness a commendable market growth during forecast period.
![]() |
![]() |
![]() |
Examples of key companies engaged in Fc region and glycoengineered antibodies market (which have also been profiled in this market report; the complete list of companies is available in the full report) include AbbVie, Alexion Pharmaceuticals, AstraZeneca, Genentech, MacroGenics and Kyowa Kirin. This market report includes an easily searchable excel database of all the companies developing Fc region and glycoengineered antibodies, worldwide.
Several recent developments have taken place in the field of Fc region and glycoengineered antibodies market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The ‘Fc Region and Glycoengineered Antibodies Market: Focus on Type of Fc Engineering and Therapeutics (3rd edition), 2021-2035’ market report features an extensive study on the current market landscape, market size, market share, market forecast, market outlook and future opportunities for the Fc region and glycoengineered antibodies market. The market research report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in Fc region and glycoengineered antibodies market, across different geographies.
![]() |
![]() |
![]() |
Amongst other elements, the market research report includes:
The key objective of Fc region and glycoengineered antibodies market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for Fc region and glycoengineered antibodies market during the forecast period. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the evolution of the market for the forecast period 2021-2035. The market report features the likely distribution of the current and forecasted opportunity across [A] type of Fc engineering (Fc protein and glyco-engineered) [B] type of therapy (monotherapy and combination therapy) [C] therapeutic area (autoimmune disorders, oncological disorders, infectious diseases and others), [D] route of administration (intravenous, subcutaneous and others), and [E] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the anticipated industry’s growth.
![]() |
![]() |
![]() |
All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this market research report are in USD, unless otherwise specified.